Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Anastrozole; Vandetanib
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 13 Dec 2016 Number of treatment arms changed from 1 to 2.
- 03 Mar 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.